Pearl Steinzor

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.

Will Shapiro, vice president of data science at Flatiron Health, discusses opportunities to implement artificial intelligence in cancer care.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.

Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.

Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS).

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Areas with high proportions of Black and Latinx residents face high rates of asthma-related emergency department visits, according to one study.

A comprehensive analysis by the Patient Access Network (PAN) Foundation explores the state of patient access for adults living with chronic conditions in the US.

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, reports promising response rates and a good safety profile with JNJ-2113 in patients with moderate to severe plaque psoriasis.

Posters presented at the American Academy of Dermatology 2024 Annual Meeting identified significant health disparities among patients living in rural areas and those with skin of color (SOC).

A study weighed the different comorbidities associated with asthma among a study population based in Finland.

Posters presented at the American Academy of Dermatology Annual Meeting demonstrated both short- and long-term efficacy and safety profiles of brodalumab in patients with moderate to severe psoriasis.

Amy S. Paller, MD, of Feinberg School of Medicine at Northwestern University, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).

Controlling emissions can lead to significant improvements in public health in surrounding communities, according to one study.

Shawn Kwatra, MD, dermatologist, John Hopkins University, discusses late breaking study results on the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis (PN).

Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, shares 16-week safety and efficacy data from the FRONTIER 2 clinical trial on JNJ-2113 for patients with moderate to severe plaque psoriasis.

Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study.

Amy S. Paller, MD, chair of the department of dermatology at Feinberg School of Medicine at Northwestern University, discussed using systemic therapies to treat children with atopic dermatitis (AD).

AnaptysBio's senior vice president of research, Martin Dahl, PhD, discusses therapeutic strategies and pathophysiological approaches to treating patients with atopic dermatitis (AD).

Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).

In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.

Monica Li, MD, medical and cosmetic dermatologist and clinical assistant professor, University of British Columbia, discusses how microneedling can address both aesthetic and medical dermatological needs across different skin types.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.

There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.

Amy S. Paller, MD, chair of dermatology, Feinberg School of Medicine at Northwestern University, discusses aspects of this year's American Academy of Dermatology (AAD) conference she is most excited about.

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

Air pollution exposure during the first 3 years of life was associated with asthma incidence, according to one study.